These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 23643745

  • 1. Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.
    Viaro R, Calcagno M, Marti M, Borrelli E, Morari M.
    Neuropharmacology; 2013 Sep; 72():126-38. PubMed ID: 23643745
    [Abstract] [Full Text] [Related]

  • 2. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
    Volta M, Viaro R, Trapella C, Marti M, Morari M.
    Exp Neurol; 2011 Mar; 228(1):126-37. PubMed ID: 21215744
    [Abstract] [Full Text] [Related]

  • 3. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
    Viaro R, Marti M, Morari M.
    Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
    [Abstract] [Full Text] [Related]

  • 4. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.
    Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C, Morari M.
    J Neurosci; 2004 Jul 28; 24(30):6659-66. PubMed ID: 15282268
    [Abstract] [Full Text] [Related]

  • 5. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
    Mabrouk OS, Marti M, Morari M.
    Neuroscience; 2010 Mar 10; 166(1):40-8. PubMed ID: 20006677
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats.
    Micheli L, Di Cesare Mannelli L, Guerrini R, Trapella C, Zanardelli M, Ciccocioppo R, Rizzi A, Ghelardini C, Calò G.
    Eur J Pharmacol; 2015 May 05; 754():73-81. PubMed ID: 25704616
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological blockage of NOP receptors decreases ventral tegmental area dopamine neuronal activity through GABAB receptor-mediated mechanism.
    Petrella M, Borruto AM, Curti L, Domi A, Domi E, Xu L, Barbier E, Ilari A, Heilig M, Weiss F, Mannaioni G, Masi A, Ciccocioppo R.
    Neuropharmacology; 2024 May 01; 248():109866. PubMed ID: 38364970
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex.
    Mela F, Marti M, Ulazzi L, Vaccari E, Zucchini S, Trapella C, Salvadori S, Beani L, Bianchi C, Morari M.
    Eur J Neurosci; 2004 Mar 01; 19(5):1317-24. PubMed ID: 15016089
    [Abstract] [Full Text] [Related]

  • 10. Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120.
    Fischetti C, Rizzi A, Gavioli EC, Marzola G, Trapella C, Guerrini R, Petersen JS, Calo G.
    Peptides; 2009 Feb 01; 30(2):248-55. PubMed ID: 18992780
    [Abstract] [Full Text] [Related]

  • 11. Activation of nociceptin/orphanin FQ-NOP receptor system inhibits tyrosine hydroxylase phosphorylation, dopamine synthesis, and dopamine D(1) receptor signaling in rat nucleus accumbens and dorsal striatum.
    Olianas MC, Dedoni S, Boi M, Onali P.
    J Neurochem; 2008 Oct 01; 107(2):544-56. PubMed ID: 18717817
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease.
    Marti M, Mela F, Fantin M, Zucchini S, Brown JM, Witta J, Di Benedetto M, Buzas B, Reinscheid RK, Salvadori S, Guerrini R, Romualdi P, Candeletti S, Simonato M, Cox BM, Morari M.
    J Neurosci; 2005 Oct 19; 25(42):9591-601. PubMed ID: 16237164
    [Abstract] [Full Text] [Related]

  • 14. Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic Gi/o protein linked pathways.
    Fantin M, Fischetti C, Trapella C, Morari M.
    Br J Pharmacol; 2007 Oct 19; 152(4):549-55. PubMed ID: 17618307
    [Abstract] [Full Text] [Related]

  • 15. Nociceptin/orphanin FQ (N/OFQ)-evoked bradycardia, hypotension, and diuresis are absent in N/OFQ peptide (NOP) receptor knockout mice.
    Burmeister MA, Ansonoff MA, Pintar JE, Kapusta DR.
    J Pharmacol Exp Ther; 2008 Sep 19; 326(3):897-904. PubMed ID: 18539652
    [Abstract] [Full Text] [Related]

  • 16. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.
    Volta M, Mabrouk OS, Bido S, Marti M, Morari M.
    J Neurochem; 2010 Dec 19; 115(6):1543-55. PubMed ID: 20950413
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.
    Calo G, Guerrini R, Rizzi A, Salvadori S, Burmeister M, Kapusta DR, Lambert DG, Regoli D.
    CNS Drug Rev; 2005 Dec 19; 11(2):97-112. PubMed ID: 16007234
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.